The new guideline for managing lupus nephritis (LN) was presented at the ACR 2024 Annual Meeting, recommending a more aggressive first-line approach using triple therapy with glucocorticoids, mycophenolate or cyclophosphamide, and a newer agent like belimumab or voclosporin. The guideline emphasizes shared decision-making with patients, reducing healthcare disparities, and considering pediatric and geriatric populations. Recommendations include proteinuria screening every 6-12 months, kidney biopsies for suspected LN, hydroxychloroquine for all SLE patients, and adjusting RAAS-I dosages as needed. Treatment should start with triple therapy for all LN patients and be maintained for 3-5 years. Monitoring and adjusting therapy as needed are essential for better long-term outcomes.
Source link
Updated Lupus Nephritis Guideline Advises Triple Therapy
